The American Journal of Managed Care

Boehringer Ingelheim Launches Phase 2 Trial of IL-11 Antibody for IPF Treatment

1. Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to phase II clinical research in idiopathic pulmonary fibrosis. News release. Boehringer-Ingelheim. January 13, 2026. Accessed ...
The American Journal of Managed Care

Oral Nalbuphine Significantly Reduces Chronic Cough in IPF

IPF-associated cough affects up to 80% of patients with IPF, substantially impairing their quality of life; consequently, ...
Healio

Angiotensin-converting enzyme inhibitor use before IPF diagnosis lowers mortality risk

Among patients with idiopathic pulmonary fibrosis, the risk for all-cause mortality was significantly lower with vs. without ...
MedPage Today on MSN

Novel Opioid Receptor Drug Cuts IPF Cough

Opioid agonist/antagonist has a big impact in phase IIb trial ...
Everyday Health on MSN

6 tips for managing chronic fatigue with IPF

Learn to manage chronic fatigue from IPF with exercise, nutrition, sleep hygiene, and energy-saving strategies.
MarketWatch

U.S. FDA approves Boehringer's JASCAYD(R) (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

The MarketWatch News Department was not involved in the creation of this content. Ingelheim, Germany/Ridgefield, Connecticut, U.S. -- Idiopathic pulmonary fibrosis (IPF) is a progressive disease, ...
Managed Healthcare Executive

Antifibrotic therapy equally effective in familial and sporadic IPF

Antifibrotic therapy shows similar efficacy in familial and sporadic IPF, with no significant differences in survival or acute exacerbations. Because familial idiopathic pulmonary fibrosis is ...
clinicaladvisor.com

Idiopathic pulmonary fibrosis treatment guidelines updated

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...
Medical Xpress

Pulmonary fibrosis has no cure. Could a cancer drug hold the answer?

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...
Yahoo

Boehringer Ingelheim drug wins FDA OK in tough-to-treat lung disease

A 3D illustration of human lungs. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Food and Drug ...
Medscape

How to Integrate Palliative Care into IPF Treatment Plans

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...
Nasdaq

PureTech’s Deupirfenidone Shows Promise in IPF Treatment

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...